Dr. Ved Srivastava is Vice President of Chemistry at Intarcia Therapeutics and President of the American Peptide Society. Prior to Intarcia, he was co-founder and Vice President of peptide chemistry of Phoundry Pharmaceuticals. Phoundry was acquired by Intarcia Therapeutics in 2015. Prior to that, he was the Head of Peptide Chemistry at GlaxoSmithKline (USA), and in the senior leadership role at Amylin Pharmaceuticals. Ved has over 25 years of expertise in peptide medicinal chemistry, peptide drug delivery and chemistry manufacturing and control (CMC) with major emphasis in drug discovery and development in metabolic diseases, CNS, and inflammation therapeutic area. He has significantly contributed to the development of three peptide-based drugs ByettaTM, SymlinTM , and BydeureonTM for the treatment of diabetes. Ved has co-authored and published more than sixty peer-reviewed manuscripts, patents, and abstracts, and is editor of four recent books focused on peptide discovery and development - (1) Peptide Therapeutics CMC - Strategy for Chemistry Manufacturing and Control (2) Peptide-based Drug Discovery: Challenges and New Therapeutics, (3) Comprehensive Medicinal Chemistry III - Biologics Medicine -Vol 6 and (4) ‘Peptide 2015’. Ved is vice-chair and member of the Peptides Expert Committee (BIO1) of the United States Pharmacopeia and serves in the governance of the FASEB, American Chemical Society (ACS), and American Peptide Society. Ved earned a Ph.D. in organic chemistry from the University of Lucknow, India.